Atrial Fibrillation

The purpose of this study is to determine if apixaban, an investigational anticoagulant (blood-thinner) is as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in subjects with atrial fibrillation and risk factors for stroke.

Sub-Investigator: Nathan Laufer, MD

Sponsor: BMS-Pfizer-PPD

Enrollment Status: Ongoing, closed to enrollment